Comparative Pharmacology
Head-to-head clinical analysis: BRETYLOL versus IBUTILIDE FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRETYLOL versus IBUTILIDE FUMARATE.
BRETYLOL vs IBUTILIDE FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bretylium tosylate is an adrenergic neuron blocking agent that inhibits norepinephrine release and enhances its reuptake, resulting in postganglionic sympathetic blockade. It also has direct antiarrhythmic effects by increasing the ventricular fibrillation threshold.
Ibutilide fumarate is a Class III antiarrhythmic agent that prolongs the atrial and ventricular refractory period by blocking the rapid component of the delayed rectifier potassium current (IKr) and also enhances the slow inward sodium current (INa), resulting in prolongation of the action potential duration and effective refractory period.
Intravenous: 5-10 mg/kg over 10 minutes, then 5-10 mg/kg every 6-8 hours as needed for arrhythmias. Intramuscular: 5-10 mg/kg, may repeat every 6-8 hours.
1 mg (10 mL of 0.1 mg/mL solution) IV infusion over 10 minutes; if arrhythmia persists after 10 minutes post-infusion, a second 1 mg dose may be administered. For patients weighing <60 kg, use 0.01 mg/kg.
None Documented
None Documented
Terminal elimination half-life is 7-11 hours in normal renal function; prolonged in renal impairment (up to 30 hours)
Terminal elimination half-life is 2–12 hours (mean 6 hours). In atrial fibrillation/flutter, the clinically effective half-life allowing for arrhythmia conversion is approximately 2–4 hours due to rapid redistribution.
Primarily renal excretion of unchanged drug (80-90%); minor biliary/fecal elimination (10-20%)
Primarily hepatic metabolism; less than 10% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 20% of total clearance.
Category C
Category A/B
Antiarrhythmic (Class III)
Antiarrhythmic (Class III)